INTRODUCTION
X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency that is caused by a block in early B-cell differentiation. Whereas, pre-B cells in the bone marrow are present in normal numbers, XLA-affected individuals have dramatically reduced numbers of circulating mature B cells (usually less than 1% of total lymphocytes), plasma cells and immunoglobulins (Igs) of all isotypes [1±3] . As a result, the affected males are predominantly prone to recurrent bacterial infections with encapsulated organisms beginning in infancy and early childhood, and at risk of disseminated infections with enteroviruses [1, 2, 4, 5] . Unless treated aggressively by regular intravenous Ig substitution and appropriate antibiotic therapy, the disease is q 2001 Blackwell Science Ltd associated with high morbidity and, in most cases, premature death as a consequence of overwhelming infection or chronic pulmonary disease [4±6] .
The gene defective in XLA has been identified and encodes as a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (Btk) [7, 8] . Btk is a cytoplasmic tyrosine kinase that contains the Src characteristic homology domains, SH3, SH2 and kinase domain (SH1) [9, 10] . On the basis of sequence homology, Btk together with the most related kinases Tec, Itk and Bmx constitute a distinct subfamily [11±14] . The members of the Tec/Btk subfamily, in addition to the SH1, SH2 and SH3 domains, and instead of the SH4 domain of the Src kinases, contain at the N-terminus a pleckstrin homology (PH) domain which is involved in the recruitment of the kinases to the cell membrane, followed by the Tec homology (TH) domain that contains a proline-rich sequence (PR) and the Btk motif [1] . Btk is expressed in all haematopoietic lineages with the exception of mature T lymphocytes and plasma cells [15] .
There is increased evidence that Btk participates in the B-cell development via the B-cell antigen receptor (BCR)-coupled phospholipase Cg (PLCg)-IP3-calcium signalling pathway [16, 17] . However, studies in Btk-deficient mice have demonstrated that Btk mutations have significant functional consequences for mast cells and macrophages, as well [17, 18] . Accumulating data indicate that Btk is also involved in the activation of stress-activated protein-kinases, JNS/SAP1/2, and thereby regulates c-Jun and other transcription factors that are important in the cytokine-gene activation [17] . Regulation of the JNK/SAP activation pathway by Btk may be related to the proapoptotic function of Btk in the programmed cell death in mast and B cells [17] .
It is inevitable that problems can arise when the diagnosis of XLA is based only on conventional methods and not on molecular analysis, particularly in individuals who show an late-onset immunodeficiency and absence of a family history of X-linked inheritance (i.e. sporadic cases), or in cases with atypical XLA phenotype (B cells more than 1% of total lymphocytes and some Ig production) resulting in a milder or later onset form of the disease. Today this has changed because the molecular analysis of Btk mutations allows the diagnosis of affected individuals as well as the determination of carrier status. Until now, over 400 unique Btk mutations have been found in patients with XLA and they are spread throughout the gene [6, 19±28] . They consist of missense, nonsense, and splicesite mutations as well as deletions and insertions and are collected in a mutation database, BTKbase [29] .
Heterozygous female XLA carriers appear immunologically normal and are perfectly healthy owing to proliferation and maturation of B cells expressing the normal Btk allele, as evidenced by the completely skewed X chromosome inactivation in their B-cell lineage [30] . The preferential utilization of only the healthy X chromosome reflects the selective disadvantage of B-cell precursors expressing the mutated Btk allele and until now it has provided a tool for XLA carrier state diagnosis in females who have informative X-chromosome allelic polymorphisms [6, 27, 31] . However, although extremely unbalanced inactivation of the X chromosome is a truly uncommon phenomenon in normal women [32] , this fact can not exclude the low possibility that a normal woman with X chromosome inactivation pattern could be erroneously considered as a XLA carrier.
In this study we report the detection and characterization of mutations in the Btk gene in 13 Greek patients from 12 unrelated families with XLA phenotype. The screening approach used was based on Reverse Transcriptase Polymerase Chain Reaction (RT±PCR) and NIRCA, while the identification of the alterations was carried out by direct sequencing. As a result, Btk mutations were identified and characterized in all the patients. Subsequently, this information was utilized to determine accurately the carrier status of female relatives using direct PCR sequencing of genomic DNA segments containing the mutated sequences.
MATERIALS AND METHODS
Patients. Thirteen patients with XLA phenotype originating from 12 unrelated families were analyzed for the presence of Btk mutations. Patients' fresh blood samples were collected from Greek centers managing patients with immunodeficiency in Athens (1, 2, 4, 6, 9, 10, 12 of Table 1 ) and Thessaloniki (3a, 7, 8, 11 of Table 1 ), while the blood of two patients (3b and 5 of Table 1 ) were collected by other paediatric clinics at diagnosis. The patients were all male, aged 6±23 years (average 13 years), with the age at diagnosis varying between 1±6 years (average 3.6 years). The phenotype of the patients was characterized by unusual susceptibility to bacterial infections, and markedly decreased serum immunoglobulin (Ig) levels and B-cell numbers (measured by levels of CD19 and/or CD20 positive cells in peripheral blood). Patients 3a, 3b, 6, 7, 10 and 12 of Table 1 showed a family history of the disease, while the rest of the patients were sporadic cases. Patient 3b of Table 1 had an atypical phenotype of the disease. Furthermore, 16 female members of seven families were screened for mutations in the Btk to identify the putative carriers. The detection of mutations in one X chromosome was performed in genomic DNA level by PCR amplification of the damaged region and PCR based direct nucleotide sequencing.
Cells. Mononuclear cells from peripheral blood were collected and separated by density gradient centrifugation. Total RNA from 2 to 4 Â 10 7 mononuclear cells was extracted using a standard guanidium thiocyanate protocol [33] . The final RNA pellet was re-dissolved in 30±50 ml TE buffer. For genomic DNA extraction, similar number of mononuclear cells was diluted in 1 ml of lysis buffer (100 mm NaCl, 10 mm Tris-HCl pH 7.4, 25 mm EDTA pH 8.0 and 0.5% SDS). Thereafter, 20 mg/ml proteinase K was added and the samples were incubated for 12±16 h at 50 8C. The samples were extracted once with phenol-chloroform and twice with chloroform and finally the nucleic acids were precipitated with ethanol. Precipitated nucleic acids were dissolved in 80±150 ml sterile distilled water. RT±PCR amplification and NIRCA analysis of patients' samples were carried out as described previously [34] .
Molecular modeling. The structural consequences of the obtained mutations were evaluated from the modeled structures of the kinase [35] and SH2 [36] domains.
Sequencing. The results obtained by the NIRCA method were verified by direct sequencing using the T7 PCR product sequencing kit, Sequenase 2.0 (Amersham, CL, USA) according to the manufactures instructions. The reaction mixtures were analyzed on 8% acrylamide/ 7 m urea gels.
PCR amplification and direct PCR sequencing in putative carriers' samples. After the characterization of Btk mutations in 7 patients (5, 7±12 of A total of 1 mg of genomic DNA was amplified in a 50-ml PCR reaction using 200 mm of each deoxynucleotide triphosphate, 30 pmoles of each primer and 1.5 U Taq Polymerase (Promega, WI, USA) in a PCR buffer supplied by manufacturer. The conditions of PCR for exon 11 were: 2 min at 94 8C followed by 30 cycles (94 8C for 60 s, 55 8C for 60 s, 72 8C for 60 s) followed by a final elongation at 72 8C for 5 min, and the size of the PCR product was 530 bp. The conditions of PCR for exon 12 were: 2 min at 94 8C followed by 32 cycles (94 8C for 60 s, 56 8C for 60 s, 72 8C for 60 s) followed by a final elongation at 72 8C for 5 min, and the size of the PCR product was 713 bp. The conditions of PCR for exon 13 were: 2 min at 94 8C followed by 30 cycles (94 8C for 60 s, 58 8C for 60 s, 72 8C for 60 s) followed by final elongation at 72 8C for 5 min, and the size of PCR product was 278 bp. The conditions of PCR for exon 14 were: 2 min at 94 8C followed by 30 cycles (94 8C for 60 s, 55 8C for 60 s, 72 8C for 60 s) followed by final elongation at 72 8C for 5 min, and the size of PCR product was 326 bp. Finally, the conditions of PCR for exon 19 were: 2 min at 94 8C followed by 30 cycles (94 8C for 60 s, 52 8C for 60 s, 72 8C for 60 s) followed by final elongation at 72 8C for 5 min, and the size of PCR product was 353 bp. Afterwards, direct PCR sequencing was performed as described above.
RESULTS
Thirteen patients, corresponding to 12 known families across Greece that have been clinically diagnosed with XLA where analyzed molecularly and found to carry mutations in the Btk gene (success rate 100%). A variety of mutations were detected including large and small deletions, small insertions, splicing mutations and missense or nonsense base substitutions. The mutations of patients 1, 3a and 3b had already been described by us in a previous report (34) , while the mutations of six patients (4, 5, 6, 7, 8 , and 11 of Table 1 ) are novel and have not appeared in the Btk mutation database (Btkbase: http://www.uta.fi/imt/ bioinfo/BTKbase/). All the mutations found in individual patients are summarized in Table 1 .
Mutations resulting in premature termination signals or abnormally sized Btk transcripts were identified in eight patients (1±3b and 6±9 of Table 1 ) and were the most frequent mutation type. Exon 8 was absent in the cDNA of two related patients (the proband and his maternal uncle), whereas exon 5 was missing in the cDNA of patient 2 (see Table 1 ). These defects were first evident upon amplification of the cDNA segments as smaller than normal-size products. Furthermore, small deletions or insertions giving rise to frame-shifts were detected in three other patients (6, 7, and 9 of Table 1 ). Base substitutions giving rise to premature termination signals were found, at codon 13 (c169C . T) in patient 1, and codon 392 (c1308C . A) in patient 8. On the other hand, single nucleotide changes leading to Btk amino acid substitutions were found in 5 patients, as shown in Table 1 . Additionally, patient 7 (Table 1 ) has a cousin with the same alteration in Btk gene (c1306±1307insA) who was not included in this study, because no clinical or immunological data were available. Based on the SH2 and kinase domain models [35, 36] the effect of the different amino acid substitutions on Btk function were evaluated (Fig. 1) . The mutation C337G affects the first residue of the bD1 secondary structure. Mutation displaces a residue from the pY 1 1 binding site and most likely either reduces the affinity to the ligands or changes the specificity of the SH2 domain. L346R causes a major change to the side chain by substituting an aliphatic chain by a much longer and charged arginine. The residue locates in the end of the bE strand and it is involved in the binding site pY 1 3. Thus, the mutation alters the binding site owing to a major change in the side chain that substitutes the neutral residue by a basic one. Furthermore, the bulky side chain will have an effect on the affinity to ligands. The importance of position 337 for ligand binding has been further illustrated by the analysis of a Btk-SH2 domain variant carrying a serine at position 337. This mutant, which has not been found in any patient, was produced by recombinant technology. It did not affect the folding of the domain, however it significantly increased its phosphotyrosine binding capacity [37] .
K430E removes the essential ATP-binding interaction of the kinase domain. This mutation has already been described previously in two other families [7, 35] . L452P affects the residue from a loop connecting the kinase domain aC and b4. Substitution by proline is likely to change the conformation of the loop and consequently the overall fold of the domain. The ring structure of the proline allows only certain torsion angles of the protein backbone and appears often in cis conformation. Finally, R641H is localized in the lower lobe of the kinase domain. The substitution replaces essentially invariant interaction of kinases. Ionic bond between E567 and Arg641 stabilizes the structure of the kinase. This CpG dinucleotide altering mutation has been described several times previously (BTKbase: http://www.uta.fi/imt/bioinfo/BTKbase/)
A carrier detection was performed at the genomic DNA level by exon-specific PCR and direct PCR sequencing. DNA was available for study from mothers and other female family members of seven patients with XLA and documented mutations in the Btk gene (Table 1) . In all instances, the analysis of the mothers' DNA revealed one abnormal allele (similar to the one found in her son) as well as one normal allele, which indicated that they were XLA carriers. Furthermore, the sisters of patients 9 and 10 and the aunts of the patients 7, 10 and 12 were found to be XLA carriers too, while the sisters of the patients 7 and 11 were not. Moreover, the aunt of patient 5 and the cousin of patient 7 were not carriers of XLA. Examples of the identification of XLA carrier status are shown in Figs 2 and 3.
DISCUSSION
We have described here the identification of Btk mutations in 13 Greek XLA patients from 12 unrelated families and this is the first report of a nationwide XLA molecular study in Greece. Our analysis performed by the PCR/NIRCA assay established an absolute concordance between the RNase cleavage and sequencing data, thus illustrating the value of NIRCA as a first step method for screening of XLA patients.
As recognized in previous studies [21, 27] , about half of the Btk mutations identified herein (7/13) were localized within the kinase (SH1) domain and the most common type of sequence modification where mutations leading to truncated Btk transcripts and/or premature termination signals (X/Y).
Two patients (3a and 3b of Table 1 ) were members of the same family (sons of two sisters) and even though they carried the same alteration in their Btk genes (skipping of exon 8), they nevertheless exhibited very different clinical phenotypes, ranging from sporadic infections (patient 3b) to severe recurrent infections (patient 3a). Immunologic evaluation revealed variation in the Ig levels and B-cell numbers. Similar cases have already been noted in the literature [38, 39] , demonstrating that other genetic and/or environmental factors are involved in phenotypic diversity of the disease.
Moreover, it is obvious by this and other studies [20, 25, 27, 28, 38, 40] that the site or type of the mutation within the Btk cannot predict the phenotype in XLA. Thus, it has become evident that different mutations within the same gene in single-gene-defect diseases could be accompanied by a range of phenotypes [41±44] .
We have analyzed the XLA carrier status in female members of seven families, after the identification of mutations of the patients. The demonstration of healthy female carriers was performed by amplification of specific region of the gene using PCR of genomic DNA, followed by direct PCR sequencing. Until now, X-chromosome inactivation pattern procedures had been followed for the identification of XLA carrier status, but these procedures are time consuming and cumbersome, while they can not preclude false positive results. The false positive results can be ascribed in the fact that some normal women (especially in the elderly) display monoclonal X-chromosome inactivation pattern without Btk or other defects [32] . On the other hand, direct PCR sequencing (at the genomic DNA level) is an accurate and reliable procedure, and precludes the presence of false positive results, while as a technique it is fast and easy. Table 1 ) established by Non-Isotopic-RnaseCleavage-Assay (NIRCA) analysis in the SK region of the Btk gene [34] . Line 1: 100 bp ladder molecular weight marker (Gibco BRL). Lines 2 and 7: cleavage products of hybrids generated with sense and antisense RNA from the patient or the wild-type control template (reveal background cleavage products) (wild type: normal individual). Lines 3±6: cleavage products by different combinations of Rnases of hybrids generated using sense RNA from the patient and antisense from the wild-type control. The arrows reveal the mutation related to the cleavage products at 360 bp and 270 bp, respectively. (B) Detection of the specific alteration (asterisks), c1356±1357insG, in the sister of the patient 9 (XLA carrier). (C) Absence of the above specific mutation in a family member of patient 10, normal control (Table 1) . After the site of the insertion the carrier display two different sequences. Table 1 ) and his putative female carriers. (A) Detection of Btk mutation c1169T . G in the patient 5 (Table 1) Thus, in seven families analyzed in this study we found that all the mothers were XLA carriers (8/8, rate 100%), while only 50% (4 out of 8) of the other relatives were carriers of the disease. This fact is concordant with other studies in the literature [27, 31] . For example in the study of Conley et al. 84% of the mothers of patients with sporadic XLA were carriers of the mutation found in their son. It is noticeable that the risk for the mother of one XLA patient to be a carrier of the disease was estimated to be ,77%, while the risk to the sister of the affected male was estimated to be half the risk compared to the mother (38%) [27] . However, only the accurate genetic analysis of the members of the affected family should facilitate the genetic counselling in families with XLA, and in this report we present a very rapid and reliable method to analyze the XLA carrier status accurately.
In conclusion, our results further demonstrate that molecular genetic testing provides an accurate tool for the definitive diagnosis of XLA and may allow accurate carrier and prenatal diagnosis for genetic counselling.
